|
PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients. |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer |
Research Funding - Novartis |
|
|
Consulting or Advisory Role - Eisai; Novartis; Roche |
Research Funding - AstraZeneca (Inst); Eisai (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Thibault De La Motte Rouge |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genomic Health; Pfizer |
Travel, Accommodations, Expenses - Hospira; Pfizer |
|
|
No Relationships to Disclose |
|
Anne-Claire Hardy-Bessard |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Novartis; pfizer; Roche |